Skip to content
BIOTON S.A. logo — Biotechnologia w trosce o pacjenta

BIOTON S.A.

Biotechnologia w trosce o pacjenta

Founded 1989 Poland Poland 257 employees Private Equity Biopharma, Biotechnology +6

General Information

Company Name BIOTON S.A.
Founded Year 1989
Location Poland Poland
Employees 257
Industries Biopharma, Biotechnology, Finance +5
Funding Stage Private Equity
Business Model B2B, B2C, D2C
Revenue Model Product Sales, Service Fee, Licensing
Social

BounceWatch is an independent company data service, not affiliated with BIOTON S.A.. To contact BIOTON S.A., visit bioton.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BIOTON S.A. compare?

A PDF of BIOTON S.A. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BIOTON S.A. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BIOTON S.A.

BIOTON S.A., operating under the slogan "Biotechnologia w trosce o pacjenta", is a leading European biotech company based in Poland and established in 1989. The company specializes in the production of human insulin, both as active pharmaceutical ingredients and in finished forms like cartridges and vials.

With a strong track record of over two decades, BIOTON S.A. holds a dominant position in the Polish market and is recognized among the top eight global commercial manufacturers of recombinant human insulin. The company emphasizes innovation through continuous investment in Polish biotechnology, leveraging local collaborations to commercialize Biotech Transfer results successfully.

Further enhancing its portfolio, BIOTON S.A. offers contract manufacturing (CMO/CDMO) and quality control (QC) services, adhering to the highest standards of Quality by Design (QbD) and current Good Manufacturing Practices (cGMP). The company also integrates pioneering therapeutic solutions for diabetes and supplies gastroenterological Foods for Special Medical Purposes (FSMP).

The last significant funding occurred on 01 July 2015 through a Private Equity Round led by CEE Equity Partners, highlighting investor confidence. While BIOTON S.A. strides forward with its expansive industry engagements spanning biopharma, biotechnology, and other sectors, it remains a promising opportunity for discerning investors looking to be part of a transformative journey in healthcare innovation.

Business keywords: Diabetes Treatment, Human Insulin Production, Recombinant Insulin, Pharmaceuticals, Contract Manufacturing Organization (CMO), Contract Development and Manufacturing Organization (CDMO), Quality Control (QC), Drug Development, Foods for Special Medical Purposes (FSMP), Therapeutics, Over-the-Counter (OTC) Products, Supply Chain, Research & Development, Innovation

Services & Products

insulin synthesis and production
biopharmaceutical research and development
patient education and specialist consultations
manufacturing of medical devices and pharmaceuticals
environmental protection in drug production

Target Customers

diabetes patients healthcare professionals pharmaceutical investors medical device users research institutions

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Private Equity Round Undisclosed 1
CEE Equity Partners
01 Jul 2015

BIOTON S.A. Alternatives & Competitors

View All Alternatives
BIOTON S.A. vs

Distributor of pharmaceuticals including ethical, over-the-counter (OTC), medical disposables, diagn...

Private Equity
27 employees
Health Care, Pharmaceutical
BIOTON S.A. vs

Insight. Innovation. Intervention.

Venture round
58 employees
Biopharma, Biotechnology
BIOTON S.A. vs
Biocon
Biocon India

Transforming Healthcare. Transforming Lives.

IPO
11576 employees
Biopharma, Biotechnology

FAQ About BIOTON S.A.

Biotechnologia w trosce o pacjenta
BIOTON S.A. was founded in 1989.
BIOTON S.A. is headquartered in Poland.
BIOTON S.A. operates in Biopharma, Biotechnology, Finance, Health Care, Supply Chain, Marketing, Clean Energy and Human Resources. Its work centres on Diabetes Treatment, Human Insulin Production, Recombinant Insulin and Pharmaceuticals. Its customers include diabetes patients, healthcare professionals and pharmaceutical investors.
BIOTON S.A. has a B2B, B2C and D2C business model. Its revenue comes from Product Sales, Service Fee and Licensing.
BIOTON S.A. has approximately 257 employees.
BIOTON S.A. has completed 1 funding round. The latest funding stage is Private Equity.
BIOTON S.A. offers: insulin synthesis and production, biopharmaceutical research and development, patient education and specialist consultations, manufacturing of medical devices and pharmaceuticals, environmental protection in drug production.
Top alternatives and competitors to BIOTON S.A. include Pharmaforte Singapore Pte Ltd, Akston Biosciences Corporation, Biocon. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BIOTON S.A. and Pharmaforte Singapore Pte Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BIOTON S.A., https://bouncewatch.com/company/bioton-sa, updated 25 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout